What is Abcuro?
Abcuro operates at the intersection of immunology and precision medicine, focusing on the development of first-in-class immunotherapies. By targeting the precise modulation of highly cytotoxic T cells, the company aims to address significant unmet medical needs in both autoimmune diseases and cancer. Its lead asset, ulviprubart, represents a sophisticated therapeutic strategy designed to provide targeted intervention where traditional treatments have historically failed. The company's market position is bolstered by its ability to attract institutional capital from firms that specialize in evidence-based healthcare innovation and long-term biopharmaceutical value creation.
How much funding has Abcuro raised?
Abcuro has raised a total of $473.3M across 5 funding rounds:
Seed
$2.3M
Series A
$50M
Series B
$155M
Series C
$200M
Series D
$66M
Seed (2016): $2.3M, investors not publicly disclosed
Series A (2021): $50M led by Pontifax, Mass General Brigham Ventures, Sanofi Ventures, RA Capital Management, Samsara BioCapital, and Hongsen Investment Group
Series B (2023): $155M supported by RA Capital Management, Redmile Group, Sanofi Ventures, and Samsara BioCapital
Series C (2025): $200M featuring Bain Capital, Foresite Capital, New Enterprise Associates, Eurofarma, Pontifax, Soleus Capital, Redmile Group, RA Capital Management, Samsara BioCapital, Mass General Brigham Ventures, BlackRock, and Sanofi Ventures
Series D (2026): $66M backed by Eurofarma, Mass General Brigham, RA Capital Management, Foresite Capital, Sanofi Ventures, Rock Springs Capital, New Leaf Venture Partners, Pontifax, Redmile Group, New Enterprise Associates, Samsara BioCapital, and Soleus Capital
Key Investors in Abcuro
RA Capital Management
A multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing their internal TechAtlas think tank to analyze clinical data.
Sanofi Ventures
The corporate venture capital arm of Sanofi, dedicated to investing in early-stage biotech and digital health companies with transformative potential in immunology and oncology.
Samsara BioCapital
A specialized investment firm that partners with scientists and drug developers to create and support the next generation of therapeutic breakthroughs in the biopharmaceutical sector.
What's next for Abcuro?
With the successful closure of this Series D round, Abcuro is well-positioned to accelerate its clinical trial pipeline and expand its operational capacity. The strategic focus will likely remain on the advancement of ulviprubart through late-stage clinical milestones, while simultaneously exploring the broader applicability of its T cell modulation platform. As the company matures, the emphasis will shift toward regulatory engagement and the potential for future commercialization, supported by a robust balance sheet and a deep bench of experienced life science investors who provide both financial resources and strategic guidance in the competitive biotechnology landscape.
See full Abcuro company page
